Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy

The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production

Medera doses final patient in high-dose HFpEF gene therapy trial

Heart failure affects an estimated 64.3 million people worldwide

FDA delays Corcept’s hypertension drug, seeks more evidence

The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence

FibroBiologics moves experimental psoriasis therapy into FDA review

The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline

Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery

The funding will accelerate Sinopia’s data-driven drug discovery efforts

CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers

The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively

Transcenta teams up with EirGenix to revolutionise biologics manufacturing

Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform

Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies

Harbour BioMed brings advanced antibody discovery platforms to the table

US House passes Bill reauthorizing FDA rare disease incentive program